Macroprolactinoma in Men with Hypogonadotrophic Hypogonadism After Dopamine Agonist Failure

Clinical Scenario

Men with macroprolactinoma and hypogonadotrophic hypogonadism who present with gynaecomastia, loss of libido, erectile dysfunction, infertility, or galactorrhoea. Macroprolactinomas in men tend to be more aggressive and show lower response rates to dopamine agonist therapy than in women.

When First-Line Therapy Is Insufficient

This protocol applies when dopamine agonist therapy (cabergoline) — the preferred first-line treatment regardless of tumour size or invasion — has failed to normalise serum prolactin levels, achieve substantial mass shrinkage, or improve visual fields.

Next-Line Approach (Partial Overview)

When dopamine agonist therapy is insufficient, a multimodal approach that may include surgical and/or radiation-based intervention is typically considered. The specific protocol depends on individual clinical assessment — the complete structured regimen is available below.

Instant Access to Structured Evidence-Based Regimens

References

Men with hypogonadotrophic hypogonadism presenting with gynaecomastia, loss of libido, erectile dysfunction and infertility or with galactorrhoea should be evaluated for hyperprolactinaemia and a prolactin-secreting adenoma (strong).

Macroprolactinomas in men are more aggressive and show lower response rates to dopamine agonist therapy than in women (strong).

Multimodal treatment with dopamine agonist therapy, surgery and/or radiation therapy is frequently required for management, with a need for close follow-up (strong).

DOI: 10.1038/s41574-023-00886-5

View source ↗